{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:59:58Z","timestamp":1790657998835,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672632"],"award-info":[{"award-number":["81672632"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972312"],"award-info":[{"award-number":["81972312"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ40579"],"award-info":[{"award-number":["2022JJ40579"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2023.e23165","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T11:55:44Z","timestamp":1701863744000},"page":"e23165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-8978","authenticated-orcid":false,"given":"Xiaotang","family":"Di","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doudou","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2023.e23165_bib1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12885-019-5467-x","article-title":"Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study","volume":"19","author":"Parsons","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23165_bib2","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"Ca - Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e23165_bib3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5694\/j.1326-5377.2005.tb07079.x","article-title":"Multiple myeloma: the present and the future","volume":"183","author":"Joshua","year":"2005","journal-title":"Med. J. Aust."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23165_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5694\/mja2.50129","article-title":"Biology and therapy of multiple myeloma","volume":"210","author":"Joshua","year":"2019","journal-title":"Med. J. Aust."},{"issue":"13","key":"10.1016\/j.heliyon.2023.e23165_bib5","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1158\/1078-0432.CCR-18-1909","article-title":"A phase I\/II trial of carfilzomib, pegylated liposomal doxorubicin, and dexamethasone for the treatment of relapsed\/refractory multiple myeloma","volume":"25","author":"Schroeder","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2023.e23165_bib6","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.2147\/CMAR.S166640","article-title":"Treatment options for refractory\/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis","volume":"10","author":"Luo","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.heliyon.2023.e23165_bib7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.canlet.2017.11.020","article-title":"Targeting signaling pathways in multiple myeloma: pathogenesis and implication for treatments","volume":"414","author":"Hu","year":"2018","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e23165_bib8","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2009-06-222943","article-title":"PI3K\/p110\u03b4 is a novel therapeutic target in multiple myeloma","volume":"116","author":"Ikeda","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23165_bib9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23165_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.12920","article-title":"PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform","volume":"166","author":"Hofmann","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2023.e23165_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.16","article-title":"PI3K\u03b4 and PI3K\u03b3 isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment","volume":"7","author":"Piddock","year":"2017","journal-title":"Blood Cancer J."},{"issue":"7629","key":"10.1016\/j.heliyon.2023.e23165_bib12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e23165_bib13","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1158\/0008-5472.CAN-14-3303","article-title":"Manic fringe promotes a claudin-low breast cancer phenotype through notch-mediated PIK3CG induction","volume":"75","author":"Zhang","year":"2015","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23165_bib14","first-page":"2105","article-title":"Notch signaling via regulation of RB and p-AKT but not PIK3CG contributes to MIA PaCa-2 cell growth and migration to affect pancreatic carcinogenesis","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23165_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/MCB.19.1.1","article-title":"c-myc target genes involved in cell growth, apoptosis, and metabolism","volume":"19","author":"Dang","year":"1999","journal-title":"Mol. Cell Biol."},{"issue":"16","key":"10.1016\/j.heliyon.2023.e23165_bib16","doi-asserted-by":"crossref","first-page":"6344","DOI":"10.1073\/pnas.0601418103","article-title":"Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation","volume":"103","author":"Mo","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e23165_bib17","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1080\/10428194.2016.1219905","article-title":"Myc is also the bad guy in myeloma","volume":"57","author":"Manasanch","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e23165_bib18","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1093\/nar\/gkz344","article-title":"c-MYC empowers transcription and productive splicing of the oncogenic splicing factor Sam68 in cancer","volume":"47","author":"Caggiano","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23165_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200725","article-title":"The phosphoinositide-3 kinase (PI3K)-\u03b4,\u03b3 inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies","volume":"13","author":"Faia","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23165_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jop.12784","article-title":"JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways","volume":"48","author":"Liu","year":"2019","journal-title":"J. Oral Pathol. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e23165_bib21","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.7150\/thno.15584","article-title":"Lycorine downregulates HMGB1 to inhibit autophagy and enhances bortezomib activity in multiple myeloma","volume":"6","author":"Roy","year":"2016","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e23165_bib22","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm1284","article-title":"Blockade of PI3K\u03b3 suppresses joint inflammation and damage in mouse models of rheumatoid arthritis","volume":"11","author":"Camps","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2023.e23165_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03986-3","article-title":"Canonical PI3K\u03b3 signaling in myeloid cells restricts infection and dampens chagasic myocarditis","volume":"9","author":"Silva","year":"2018","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e23165_bib24","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23165_bib25","first-page":"422","article-title":"Growth inhibition effect of matrine on K562 cells mediated by IL-6\/JAK\/STAT3 signaling pathway","volume":"36","author":"Ma","year":"2015","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e23165_bib26","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"20","key":"10.1016\/j.heliyon.2023.e23165_bib27","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2023.e23165_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: every year a new standard?","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23165_bib29","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.228395","article-title":"The cell biology behind the oncogenic PIP3 lipids","volume":"132","author":"Carrera","year":"2019","journal-title":"J. Cell Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23165_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23165_bib31","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23165_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-021-03685-w","article-title":"Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib","volume":"12","author":"Cao","year":"2021","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23165_bib33","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","article-title":"Targeting MYC in multiple myeloma","volume":"32","author":"Jovanovic","year":"2018","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.heliyon.2023.e23165_bib34","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e23165_bib35","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181027","article-title":"Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells","volume":"38","author":"Yao","year":"2018","journal-title":"Biosci. Rep."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23165_bib36","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/15384047.2018.1529112","article-title":"Montelukast enhances cytocidal effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway","volume":"20","author":"Tong","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.heliyon.2023.e23165_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216019","article-title":"Luteolin inhibits the TGF-beta signaling pathway to overcome bortezomib resistance in multiple myeloma","volume":"554","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23165_bib38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Targeted Ther."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023103732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023103732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:50:42Z","timestamp":1790657442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023103732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844023103732"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23165","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e23165"}}